CV Sciences, Inc. (OTCQB: CVSI) announced this morning that the company’s second quarter 2018 revenue is expected to have reached $12.3 million, which is up 203% compared to their second quarter last year. The company owns the well-known hemp derived CBD product brand +CBD oil.
CV Sciences owns their own pharmaceutical drug division that works specifically on the research and development of commercial CBD Products. Their subsidiary +CBD Oil focused on the manufacturing, marketing, and distribution of Cannabidiol based products such as soft gel capsules, powdered capsules, sublingual tinctures, topical and sprays.
In the announcement, CV Sciences indicated that the company has increased their retail store count to 1,968 organic health food stores as of the end of June 2018. By allowing customers to purchase online, as well as, through retail outlets across the country the company has been able to significantly increase its visibility with consumers.
CV Sciences, Inc. currently has a market cap of $234.82m and is trading at 2.769 per share.
You may be interested
Featured CCT Interview with CEO of Eden Labs AC BraddockEditor - August 20, 2018
Eden Labs LLC. has been developing and providing plant based extraction equipment out of Seattle, Washington for some of the largest and most respected companies involved in…
VividGro, a Pegasus Capital Advisors Portfolio Company, Announces Partnership with Merida Capital PartnersEditor - August 17, 2018
Partnership to Focus on Growth in Horticultural and Cannabis Industries VividGro, LLC, a portfolio company of private equity firm Pegasus Capital Advisors (Pegasus), today announced it has…
Harborside to Go Public Via Canadian Reverse Takeover in Deal Valued at C$200 MillionEditor - August 15, 2018
Harborside, a California based cannabis dispensary brand with multiple locations, is planning the reverse takeover of Canadian public company Lineage Grow Company Ltd. (CSE: BUDD). Lineage is…